

A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People

NCT07238816

Status	RECRUITING
Phase	Phase 1
Sponsor	Novo Nordisk A/S
Enrollment	80 participants

Key Eligibility Criteria

Inclusion (5)

- Male.
- Age 18-45 years (both inclusive) at the time of signing informed consent.
- Body mass index between 18.5 and 29.9 kilogram per square meter (kg/m²) (both inclusive) at screening.
- Body weight between 60.0 and 100.0 kilogram (kg) (both inclusive) at screening.
- Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion (9)

- Factor VIII activity greater than or equal to (e) 150 percentage (%) at screening.
- Increased risk of thrombosis, e.g. known history of personal or first-degree relative(s) with unprovoked deep vein thrombosis.
- Any clinical signs or established diagnosis of venous or arterial thromboembolic disease.
- Any of the thrombophilia markers listed below:
- Lupus anticoagulant, anti-cardiolipin antibody Immunoglobulin G (IgG) and Immunoglobulin M (IgM) or anti-²glycoprotein I antibody (IgG and IgM) outside the normal laboratory range at screening.
- ... and 4 more (see full listing online)

Locations (1 total)

Altasciences Clinical LA, Inc., Cypress, California, United States